Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2009

Conditions

Chronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia

Interventions

DRUG

Nilotinib

Trial Locations (1)

Novartis Investigative Site, Aichi